GleamWall
中文EN

AGEN AGENUS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1098972 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY25.4%
TTM net income YoY187.7%
TTM EPS YoY114.6%
Revenue 3-yr CAGR9.9%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin38.9%
Net margin23.0%
FCF margin-77.5%
EBITDA margin40.6%

Returns

ROE—
ROA12.9%
ROIC (approx.)—
Asset turnover0.56x

Leverage & solvency

Liabilities / assets145.7%
Debt / equity—
Current ratio0.73x
Interest coverage0.85x

Cash quality & payout

Operating cash flow / net income-3.37x
Accruals ratio56.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue$31.49M$34.52M$33.74M$34.20M$30.23M$25.69M$24.07M$26.84M
Cost of revenue$0$0$0$0$642,000$243,000$137,000$118,000
Gross profit$31.49M$34.52M$33.74M$34.20M$29.59M$25.45M$23.93M$26.72M
R&D expense$11.65M$14.76M$11.82M$7.51M$23.60M$26.71M$21.52M$33.77M
SG&A expense$8.43M$8.47M$6.86M$12.29M$10.86M$15.52M$15.72M$20.93M
Operating income$11.41M$11.29M$15.05M$14.40M-$4.54M-$16.71M-$13.31M-$25.90M
Interest expense$14.93M$15.36M$14.69M$16.05M$13.24M$13.34M$12.98M$21.11M
Net income$2.73M-$550,000$39.23M-$10.58M$63.91M-$27.95M-$25.27M-$45.86M
EBITDA$11.92M$11.81M$15.64M$14.99M-$1.51M-$13.54M-$10.11M-$22.64M
EPS (basic)0.02-0.011.03—2.00-1.00-1.03—
EPS (diluted)0.02-0.011.02—1.94-1.00-1.03—
Weighted avg. shares (diluted)83.27M41.34M38.28M—32.86M28.12M24.47M—
Balance sheet
Cash & equivalents$66.94M$18.74M$35.00M$3.00M$3.46M$9.53M$18.49M$40.44M
Short-term investments$20.00M——$0————
Receivables$17.08M$14.72M$6.56M$1.83M$538,000$709,000$354,000$407,000
Current assets$148.31M$78.81M$95.28M$133.44M$133.95M$13.34M$23.14M$45.57M
PP&E, net$13.89M$14.32M$14.95M$15.47M$15.99M$112.72M$117.03M$120.09M
Goodwill$24.09M$24.09M$24.09M$24.09M$24.09M$24.09M$24.09M$24.09M
Intangibles$2.80M$2.88M$2.96M$3.04M$3.12M$3.21M$3.29M$3.38M
Total assets$245.55M$172.69M$186.46M$226.80M$233.89M$185.22M$200.20M$226.27M
Current liabilities$203.69M$231.82M$249.24M$323.49M$287.13M$234.56M$208.30M$221.40M
Short-term debt$5.35M$30.07M$30.19M$44.66M$10.61M$10.72M$731,000$2.70M
Long-term debt$24.43M$30.07M$30.19M$0$23.60M$23.15M$32.85M$30.47M
Total debt$29.78M$60.14M$60.39M$44.66M$34.21M$33.87M$33.58M$33.17M
Total liabilities$357.70M$378.54M$414.44M$504.66M$514.76M$521.53M$522.60M$532.70M
Shareholders' equity-$105.37M-$199.07M-$221.22M-$271.11M-$274.14M-$354.60M-$341.85M-$326.38M
Net debt-$37.15M$41.40M$25.39M$41.66M$30.75M$24.34M$15.09M-$7.27M
Shares outstanding45.21M42.62M38.52M35.32M32.81M30.00M26.56M23.63M
Cash flow statement
Operating cash flow-$20.09M-$31.20M-$35.95M-$16.62M-$14.74M-$20.22M-$25.62M-$28.65M
Capital expenditure$0$0$0$0$0$1,000$5,000$73,000
Free cash flow-$20.09M-$31.20M-$35.95M-$16.62M-$14.74M-$20.22M-$25.62M-$28.73M
Investing cash flow-$19.88M$267,000$68.95M$780,000$76,000$281,000$57,000-$21,000
Financing cash flow$87.56M$14.68M-$993,000$15.37M$6.68M$10.94M$3.59M$24.37M
Depreciation & amortization$513,000$517,000$583,000$597,000$3.03M$3.17M$3.20M$3.26M
Stock-based compensation$2.92M$3.26M$1.10M$3.46M$2.81M$3.44M$3.48M$4.67M

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.